Table 3 Association of unweighted PRS in different subgroups of endometriosis patients
From: Applicability of polygenic risk scores in endometriosis clinical presentation
Crude OR (95% CI) | p-value | Adj. OR (95% CI) | p-value | |||
|---|---|---|---|---|---|---|
Isolated/spread | Isolated/spread | p-value | ||||
Quartile 1 | 8/19 | 0.027 | 1.000 | 1.000 | ||
Quartile 2 | 17/23 | 0.570 0.202–1.607 | 0.288 | 0.459 (0.137–1.537) | 0.206 | |
Quartile 3 | 23/16 | 0.293 (0.103–0.832) | 0.021 | 0.182 (0.052–0.630) | 0.007 | |
Quartile 4 | 8/22 | 1.158 0.364–3.680) | 0.804 | 0.741 (0.197–2.781) | 0.657 | |
P for trend | 0.349 | |||||
No GI tract involvement /GI tract involvement | No GI tract not involvement /GI tract involvement | p-value | ||||
Quartile 1 | 21/6 | 0.029 | 1.000 | 1.000 | ||
Quartile 2 | 35/5 | 0.500 (0.136–1.843) | 0.298 | 0.196 (0.037–1.044) | 0.056 | |
Quartile 3 | 33/6 | 0.656 (0.186–2.310) | 0.512 | 0.413 (0.090–1.897) | 0.256 | |
Quartile 4 | 18/18 | 2.333 (0.728–7.479) | 0.154 | 2.354 (0.557–9.950) | 0.244 | |
P for trend | 0.065 | |||||
No GI symptoms/ GI symptoms | No GI-symptoms/ GI-symptoms | p-value | ||||
Quartile 1 | 5/24 | 0.238 | 1.000 | 1.000 | ||
Quartile 2 | 3/36 | 2.500 (0.546–11.450) | 0.238 | 5.515 (0.666–45.659) | 0.113 | |
Quartile 3 | 6/33 | 1.146 (0.313–4.196) | 0.837 | 1.265 (0.238–6.722) | 0.782 | |
Quartile 4 | 8/23 | 0.599 (0.171–2.101) | 0.424 | 0.410 (0.075–2.236) | 0.303 | |
P for trend | 0.146 | |||||
No hormone therapy /hormone therapy | No hormone therapy /hormone therapy | p-value | ||||
Quartile 1 | 13/16 | 0.484 | 1.000 | 1.000 | ||
Quartile 2 | 22/19 | 0.702 (0.270–1.824) | 0.467 | 0.507 (0.161–1.600) | 0.247 | |
Quartile 3 | 25/14 | 0.455 (0.170–1.214) | 0.116 | 0.250 (0.075–0.829) | 0.023 | |
Quartile 4 | 17/14 | 0.669 (0.242–1.852) | 0.439 | 0.473 (0.139–1.604) | 0.229 | |
P for trend | 0.128 |